This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F03%3A00009442%21RIV08-MSM-14110___/
dctermshttp://purl.org/dc/terms/
n8http://localhost/temp/predkladatel/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F03%3A00009442%21RIV08-MSM-14110___
rdf:type
n13:Vysledek skos:Concept
dcterms:description
The ranomized, muticenter, phase III trial was conducted to compare the tolerability of gemcitabine plus cisplatine (GP) vs. gemcitabine plus carpolatin (GC). The enroled patients in GC and GP arm were balanced for demographic and disease characteristics. Both GP and GC are ffective options, the GC arm offering the advantage to pts unable to receive cisplatin. The ranomized, muticenter, phase III trial was conducted to compare the tolerability of gemcitabine plus cisplatine (GP) vs. gemcitabine plus carpolatin (GC). The enroled patients in GC and GP arm were balanced for demographic and disease characteristics. Both GP and GC are ffective options, the GC arm offering the advantage to pts unable to receive cisplatin. The ranomized, muticenter, phase III trial was conducted to compare the tolerability of gemcitabine plus cisplatine (GP) vs. gemcitabine plus carpolatin (GC). The enroled patients in GC and GP arm were balanced for demographic and disease characteristics. Both GP and GC are ffective options, the GC arm offering the advantage to pts unable to receive cisplatin.
dcterms:title
Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial
skos:prefLabel
Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial
skos:notation
RIV/00216224:14110/03:00009442!RIV08-MSM-14110___
n3:strany
65
n3:aktivita
n17:Z
n3:aktivity
Z(MSM 141100003), Z(MZ06526970501)
n3:cisloPeriodika
sup 2
n3:dodaniDat
n9:2008
n3:domaciTvurceVysledku
n10:2428245 n10:5467829
n3:druhVysledku
n6:J
n3:duvernostUdaju
n18:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
608034
n3:idVysledku
RIV/00216224:14110/03:00009442
n3:jazykVysledku
n11:eng
n3:klicovaSlova
Non Small Cell Lung Cancer; Stage IIIb and IV; Gemcitabine; Cisplatin; Carboplatin
n3:klicoveSlovo
n7:Non%20Small%20Cell%20Lung%20Cancer n7:Stage%20IIIb%20and%20IV n7:Cisplatin n7:Carboplatin n7:Gemcitabine
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[D5F044EBA000]
n3:nazevZdroje
Lung Cancer
n3:obor
n12:FC
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
10
n3:rokUplatneniVysledku
n9:2003
n3:svazekPeriodika
41
n3:tvurceVysledku
Zatloukal, Petr Kolek, Vítězslav Roubec, Martin Pešek, Miloš Havel, Libor Zemanová, Milada Sixtová, Dimka Petruzelka, Luboš Skřičková, Jana Průša, Petr
n3:zamer
n14:MZ06526970501 n14:MSM%20141100003
s:issn
0169-5002
s:numberOfPages
1
n8:organizacniJednotka
14110